4-(tert-butyl)-N-((2-methoxyphenyl)thiocarbamoyl)benzamide | 791795-15-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(tert-butyl)-N-((2-methoxyphenyl)thiocarbamoyl)benzamide
• 英文别名: 4-tert-butyl-N-[(2-methoxyphenyl)-carbamothioyl]benzamide；4-tert-butyl-N-[(2-methoxyphenyl)carbamothioyl]benzamide
• CAS: 791795-15-8
• 化学式: C₁₉H₂₂N₂O₂S
• 分子量: 342.462
• InChiKey: YTZAYSYJIAPLTQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  82.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对叔丁基苯甲酰氯 以 乙腈 为溶剂， 反应 5.0h， 生成 4-(tert-butyl)-N-((2-methoxyphenyl)thiocarbamoyl)benzamide
  参考文献：
  名称：

  酰基硫脲作为新型强效流感病毒非核苷聚合酶抑制剂的合理设计和优化

  摘要：

  有证据表明，快速进化的病毒亚变体有可能使当前的疫苗和抗流感药物失效。因此，探索抗流感药物的新支架或新靶点刻不容缓。在此，我们报告了通过支架跳跃策略产生的一系列酰基硫脲衍生物的发现，作为针对甲型和乙型流感亚型的有效抗病毒剂。最有效的化合物10m对 H1N1 增殖表现出亚纳摩尔活性 (EC 50  = 0.8 nM)，并对其他流感病毒株表现出抑制活性，包括乙型流感病毒和 H1N1 变种（H1N1、H274Y）。此外，成药性评估​​表明，10m表现出良好的药代动力学特性，并且在来自三个不同物种的肝微粒体制剂以及人血浆中代谢稳定。体外和体内毒性研究证实10m具有很高的安全性。此外，10m在致死性流感病毒小鼠模型中表现出令人满意的抗病毒活性。此外，机理研究表明，这些酰基硫脲衍生物通过靶向流感病毒RNA依赖性RNA聚合酶来抑制流感病毒增殖。因此， 10m是进一步探索流感治疗方案的潜在先导化合物。

  DOI：

  10.1016/j.ejmech.2023.115678

文献信息

• [EN] INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS<br/>[FR] INHIBITEURS ET PROCÉDÉS D'INHIBITION DE PATHOGÈNES BACTÉRIENS ET VIRAUX
  申请人：SIGA TECHNOLOGIES INC

  公开号：WO2011103375A1

  公开（公告）日：2011-08-25

  Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.

  本发明涉及化合物、药物组合物和治疗病毒和细菌感染的方法，通过给予一定量的硫脲化合物，特别是酰基硫脲、羧酰亚硫脲和S-烷基异硫脲衍生物和类似物，以治疗有效量的方法。
• Inhibitors and Methods of Inhibiting Bacterial and Viral Pathogens
  申请人：Allen Robert D.

  公开号：US20130195796A1

  公开（公告）日：2013-08-01

  Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.

  本发明涉及一种使用某些硫脲化合物（具体为酰硫脲、羧基亚硫脲和S-烷基异硫脲衍生物和类似物）以治疗病毒和细菌感染的药物组合物和方法，通过以治疗有效剂量进行给药。
• INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS
  申请人：SIGA TECHNOLOGIES, INC.

  公开号：US20160081950A1

  公开（公告）日：2016-03-24

  Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.

  本发明涉及一种治疗病毒和细菌感染的化合物、药物组合物和方法，通过给予一些硫脲化合物，特别是酰基硫脲、羧酸亚胺基硫脲和S-烷基异硫脲衍生物和类似物，在治疗有效的剂量下进行治疗。
• Inhibitors and methods of inhibiting bacterial and viral pathogens
  申请人：Siga Technologies, Inc.

  公开号：EP2865668A2

  公开（公告）日：2015-04-29

  Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.

  本发明公开了治疗病毒和细菌感染的化合物、药物组合物和方法，通过施用某些硫脲化合物，特别是酰基硫脲、羧酰亚胺基硫脲和 S-烷基异硫脲衍生物及类似物，达到治疗有效量。
• SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity
  作者：James R. Burgeson、Amy L. Moore、Jordan K. Boutilier、Natasha R. Cerruti、Dima N. Gharaibeh、Candace E. Lovejoy、Sean M. Amberg、Dennis E. Hruby、Shanthakumar R. Tyavanagimatt、Robert D. Allen、Dongcheng Dai

  DOI：10.1016/j.bmcl.2012.05.035

  日期：2012.7

  A series of acylthiourea derivatives were designed, synthesized, and evaluated for broad-spectrum antiviral activity with selected viruses from Poxviridae (vaccinia virus) and two different genera of the family Bunyaviridae (Rift Valley fever and La Crosse viruses). A compound selected from a library screen, compound 1, displayed submicromolar antiviral activity against both vaccinia virus (EC50 = 0.25 mu M) and La Crosse virus (EC50 = 0.27 mu M) in cytopathic effect (CPE) assays. SAR analysis was performed to further improve antiviral potency and to optimize drug-like properties of the initial hits. During our analysis, we identified 26, which was found to be nearly fourfold more potent than 1 against both vaccinia and La Crosse viruses. Selected compounds were further tested to more fully characterize the spectrum of antiviral activity. Many of these possessed single digit micromolar and sub-micromolar antiviral activity against a diverse array of targets, including influenza virus (Orthomyxoviridae), Tacaribe virus (Arenaviridae), and dengue virus (Flaviviridae). (C) 2012 Elsevier Ltd. All rights